The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Sarepta Shares Get a 35% Boost from FDA Approval of 2nd DMD Drug

  ()
Sarepta Therapeutics shares traded 35% higher after the firm reported that the FDA approved its second RNA exon-skipping treatment drug VYONDYS 53 injection for the treatment of Duchenne's Muscular Dystrophy in patients amenable to skipping Exon 53. read more >

Assertio Therapeutics' Shares Jump 50% on Sale of Shingles Pain Drug to Alvogen

  ()
Assertio Therapeutics' shares rose 50% after the firm reported that it has agreed to sell all rights to its Gralise drug used in the treatment of pain from shingles to Alvogen for $127.5 million. The transaction is expected to close in January 2020. read more >

Proteostasis Therapeutics Reports Positive Results from European Cystic Fibrosis Research

  ()
Proteostasis Therapeutics' shares traded higher after the company reported positive results in its European Cystic Fibrosis study of organoids grown from human stem cells. The firm believes the ongoing ex-vivo study supports initiation of a human clinical trial in mid-2020, and potential for a Marketing Authorization Application in 2021. read more >

Avid Bioservices' Shares Rise on Q2/20 Earnings and Confirmed Outlook

  ()
Shares of Avid Bioservices traded higher, reaching a new 52-week high, after the firm reported Q2/20 earnings and reaffirmed its revenue guidance for Full-Year 2020. read more >

Analyst Believes Biopharma's Alzheimer's Treatment Could Be Superior to Biogen's

Research Report
  ()
How this company's Alzheimer's therapeutic compares to an advanced-stage competitor is outlined in a Dawson James Securities note. read more >

ArQule Shares Double on Proposed $2.7 Billion Tender Offer from Merck

  ()
ArQule Inc. shares traded more than 100% higher after the company entered into definitive agreement to be acquired by a Merck subsidiary company for $20 per share. The deal is valued at $2.7 billion and is expected to close in the early part of Q1/20. read more >

Cassava Sciences' Shares Trade Up 20% on Updated Phase 2a Alzheimer's Data

  ()
Shares of Cassava Sciences traded 20% higher after the firm presented additional data from the Phase 2a study of its investigational drug candidate PTI-125 for Alzheimer's disease to the Clinical Trials on Alzheimer's Disease conference in San Diego, Calif. read more >

Aurinia Pharma Shares Open 100% Higher on Phase 3 Lupus Data

  ()
Shares of Aurinia Pharmaceuticals traded much higher after it reported positive results from its Phase 3 AURORA trial of Voclosporin for treatment of lupus nephritis. The company plans to submit a New Drug Application to the FDA in H1/20. read more >

Immuno-Oncology Firm Expands Agreement with AbbVie

Research Report
  ()
The revisions to the existing arrangement between the two U.S. firms are discussed in a ROTH Capital Partners report. read more >

INmune Bio Targeting Cancer, Alzheimer's and NASH Simultaneously

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research initiates coverage on this clinical-stage biotech whose drug candidate works to strengthen the innate immune system. read more >

Protagonist Therapeutics Shares Trade Up 70% on Phase 2 Transfusion Trial Results

  ()
Newark, Calif.-based Protagonist Therapeutics' shares traded 70% higher after the firm reported preliminary Phase 2 results for Hepcidin Mimetic PTG-300 in the treatment of transfusion dependent beta-thalassemia. read more >

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

  ()
Axsome Therapeutics shares traded higher after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. read more >

Kodiak Shares Soar on $225 Million Royalty Deal for Retinal Drug

  ()
Shares of Kodiak Sciences traded more than 100% higher at times after the company reported that it entered into a $225 million royalty agreement for the firm's KSI-301 used in the treatment of retinal vascular diseases including age-related macular degeneration and diabetic eye diseases. read more >

ChemoCentryx Shares Spike 300% on Phase 3 ANCA Vasculitis Trial Results

  ()
Shares of ChemoCentryx Inc. opened greater than 330% higher after the firm reported positive topline data from its pivotal Phase 3 ADVOCATE trial of Avacopan in treatment of ANCA-associated vasculitis. read more >

Coverage Initiated on Maker of Antibiotic-Free Supplement for Livestock Feed

Research Report
  ()
The highlights of this investment story are outlined in a Zacks Small-Cap Research report. read more >

Intercept Pharma Shares Rise on FDA Acceptance of NDA for Liver Fibrosis Treatment

  ()
Shares of Intercept Pharmaceuticals rose after the company reported that the U.S. Food and Drug Administration accepted its NDA for obeticholic acid (OCA) for the treatment of liver fibrosis due to NASH and granted priority review status. read more >

EyeGate Pharma Shares Looking Up on Pivotal PRK Ocular Bandage Gel Study Data

  ()
EyeGate Pharmaceuticals shares opened nearly 85% higher after the company reported select topline data demonstrating that it met its primary endpoint in its cornea wound repairs pivotal photorefractive keratectomy study using the firm's Ocular Bandage Gel eye drop. read more >

Hepion Pharma Shares Climb 50% Higher on NASH Liver Disease Treatment Results

  ()
Shares of Hepion Pharmaceuticals opened higher after the company reported that its anti-fibrotic agent CRV431 prevented the development of liver cirrhosis in a highly aggressive, preclinical liver disease model. read more >

Kiniksa Pharma Awarded FDA Breakthrough Therapy Status for Pericarditis Treatment Drug

  ()
Shares of Kiniksa Pharmaceuticals opened nearly 30% higher after the firm reported that the FDA granted Breakthrough Therapy designation for Rilonacept for the treatment of recurrent pericarditis. read more >

Myovant Sciences Shares Up 110% on Phase 3 Advanced Prostate Cancer Data

  ()
Shares of Myovant Sciences opened 120% higher after the firm reported a 97% response rate in its Phase 3 HERO Study of oral Relugolix in men with advanced prostate cancer. In the study, Relugolix achieved all six key secondary endpoints and the firm expects to submit a New Drug Application in Q2/20. read more >

Karuna Shares Jump 375% Higher on Phase 2 Acute Psychosis Treatment Trial Data

  ()
Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia. read more >

Sales of Antibiotic Alternative for Livestock Feed Accelerate in Asia

  ()
With antibiotic resistance a major health issue, the search is on for effective alternatives to replace antibiotics in livestock feed to promote growth. read more >

Plus Therapeutics Shares Trade Higher on Q3 Earnings and Business Restructuring

  ()
Plus Therapeutics shares traded higher after the firm reported Q3/19 financial and business results. In the most recent quarter, the company completed the change of its name, relocated its headquarters to Austin, and raised $15 million for R&D and working capital. read more >

Exicure's Collaboration with Allergan on Treating Hair Loss Disorders Sends Shares Higher

  ()
Shares of Exicure Inc. opened 30% higher after the firm reported that it entered into a collaboration agreement with Allergan to discover and develop SNA-based treatments for hair loss disorders. The terms of the deal provide for a $25 million upfront payment to Exicure with the potential to grow to $750 million. read more >
News Update

Clinical Trial Results for Alcoholic Hepatitis Drug Delivered in Webcast

News Update
  ()
The online presentation coincides with The Liver Meeting 2019, at which data also are shared. read more >
Showing Results: 1 to 25 of 127 Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"With higher uranium prices, EFR could ramp up production the fastest." ❭
– Mike Kozak, Cantor Fitzgerald
"POE's Q3/19 results were in line with our forecasts." ❭
– Bill Newman, Mackie Research Capital
"A worker bee like DEFN is a good spot to add to your watchlist." ❭
– Chris Parry, Equity Guru
"NTAR could well turn out to be a CA$20+ stock." ❭
– Clive Maund, CliveMaund.com
"LIO shouldn't lack for news flow in the new year." ❭
– Brien Lundin, Gold Newsletter (Jefferson Financial)